The amphotericin B lipid complex or Abelcet: Its Belgian connection, its mode of action and specificity. A review

Acta Clinica Belgica

Volumn 57, Issue 2, 2002, Pages 53-57

  Trouet, A ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Amphotericin B; Amphotericin B lipid complex; Antifungal therapy; Fungal infections; Liposomal amphotericin

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ANTIFUNGAL ACTIVITY; ARTICLE; BINDING AFFINITY; BONE MARROW TOXICITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TISSUE LEVEL; HUMAN; IMMUNITY; MYCOSIS; NEPHROTOXICITY;

EID: 0036305387     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2002.014     Document Type: Article

References (24)

1. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
2. Antimicrobial agents: Antifungal agents
3. Antifungal agents. Part I. Amphotericin preparations and flucytosine
4. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: A review
5. Infections in the cancer patient
6. Amphotericin B: Current undertanding of mechanism of action
7. Amphotericin B. New life for an old drug
8. Lipid formulations of amphotericin B: Recent progress and future directions
9. Unusual lipid structures selectively reduce the toxicity of amphotericin B
10. Amphotericn B lipid complex (ABLC): A molecular rationale for the attenuation of amphotericin B related toxicities
11. Treatment and prophylaxis of disseminated infection due to Candida Albicans in mice with liposome-encapsulated amphotericin B
12. Carrier effects on biological activity of amphotericin B
13. Inhibition of the interaction between lipoproteins ans amphotericin B by some delivery systems
14. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats
15. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations
16. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity
17. Comparative internalization and recycling of different amphotericin B formulations by macrophage-like cell line J774
18. Ambisome (liposomal amphotericin B): A comparative review
19. Receptor-mediated endocytosis of mannose glycoconjugates by macrophages: Characerization and evidence for receptor recycling
20. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agent
21. Carbohydrate-specific receptors of the liver
22. Cell targeting of primaquine
23. Acetylated low-density lipoprotein as a vehicle for antiinfectious drugs: Preparation and antileishmanial activity of Ac-LDL containing ketoconazoleoleate
24. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: Application to doxorubicin and preliminary in vitro and in vivo studies